TrianglePUBLICATIONS · 27992268
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2017 Feb 10
- First author
- Trappe RU
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Trappe RU
- type
- Author
- name
- Dierickx D
- type
- Author
- name
- Zimmermann H
- type
- Author
- name
- Morschhauser F
- type
- Author
- name
- Mollee P
- type
- Author
- name
- Zaucha JM
- type
- Author
- name
- Dreyling MH
- type
- Author
- name
- Dührsen U
- type
- Author
- name
- Reinke P
- type
- Author
- name
- Verhoef G
- type
- Author
- name
- Subklewe M
- type
- Author
- name
- Hüttmann A
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Trappe RU
- type
- Author
- name
- Dierickx D
- type
- Author
- name
- Zimmermann H
- type
- Author
- name
- Morschhauser F
- type
- Author
- name
- Mollee P
- type
- Author
- name
- Zaucha JM
- type
- Author
- name
- Dreyling MH
- type
- Author
- name
- Dührsen U
- type
- Author
- name
- Reinke P
- type
- Author
- name
- Verhoef G
- type
- Author
- name
- Subklewe M
- type
- Author
- name
- Hüttmann A
- type
- Author
- bibliography ids
- nci-bib-e60a36b920b2aa8d197df23b
- book metadata
- content sha256
- af8060772078cf3d2290f72b8266b33d8da684762b776365c6f9a9a1f134b0db
- document type
- citation
- dois
- 10.1200/JCO.2016.69.3564
- electronic publication date
- display
- 2016 Dec 19
- precision
- day
- year
- 2016
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:27992268
- immutable id
- pubmed:27992268@af8060772078cf3d2290f72b8266b33d8da684762b776365c6f9a9a1f134b0db
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 5
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 536-543
- volume
- 35
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 27992268
- provenance
- batch id
- 7a1288ac8bb5f9826304
- provider
- NCBI PubMed ESummary
- record sha256
- 5d38a8ce9f98d8faa119cb5da7f79242a5c38cc4e6b13c421df703a8bef13e9a
- response sha256
- 0e879bec8c19d1cfda5629dca8745b04155d18cf54361825d4c070aebad2984d
- retrieved at
- 2026-09-09T23:47:23.138359+00:00
- publication date
- display
- 2017 Feb 10
- precision
- day
- year
- 2017
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Preserved source evidence · Independent clinical review pending · Not medical advice